BRAF and B-cell chronic lymphocytic leukemia: This revised review summarizes the reported frequency, mutation spectrum, co-mutation patterns, treatment-era associations, and clinical implications of BRAF alterations in adult CLL, with explicit separation of chemoimmunotherapy-dominant cohorts from targeted-therapy-era cohorts.<h4>Recent findings</h4>Across published studies, BRAF mutations are usually detected in approximately 2-6% of unselected CLL cohorts, with higher frequencies in biologically enriched or treatment-selected populations.